Publications by authors named "Deqiang Lv"
Article Synopsis
- The NEOTAX phase 2 study explored how effective and safe the combination of toripalimab and axitinib is for patients with clear cell renal cell carcinoma and inferior vena cava tumor thrombus.
- Out of 25 patients, 44% showed a reduction in thrombus level, with a median decrease in tumor thrombus length of 2.3 cm, while 61.9% had changes in their surgical approach.
- The study found promising progression-free survival rates (25.3 months median; 89.1% at 1 year) and noted no severe treatment-related adverse events, suggesting that the combination therapy effectively downstages the tumor and improves surgical outcomes.